Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Genmab is well-positioned for future growth in the biotechnology sector due to its track record of profitability, strong balance sheet, solid positioning in multiple myeloma treatment with DARZALEX, and a broad pipeline with potential for numerous clinical data catalysts. They use a discounted cash flow approach to value the company and have assigned a 12-month price objective of $39 per share, with a 100% probability of approval for DARZALEX and other high probabilities for pipeline candidates targeting various oncologic indications. Risks include potential slowing of DARZALEX sales, failure to obtain label extensions for DARZALEX, and negative results from EPKINLY trials, among other risks.

Bears say

Genmab is heavily reliant on DARZALEX, their leading

GMAB has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 7 analysts, GMAB has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.